Last reviewed · How we verify
AZT+3TC+EFV
AZT+3TC+EFV is a Small molecule drug developed by Hospital Clinic of Barcelona. It is currently FDA-approved.
AZT (Zidovudine) and 3TC (Lamivudine) are antiretroviral medications used to treat HIV infections. Efavirenz (EFV) is a small molecule antiretroviral medication that targets HIV.
At a glance
| Generic name | AZT+3TC+EFV |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2,PHASE3)
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth (PHASE3)
- The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs (PHASE2)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART
- Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZT+3TC+EFV CI brief — competitive landscape report
- AZT+3TC+EFV updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI
Frequently asked questions about AZT+3TC+EFV
What is AZT+3TC+EFV?
AZT+3TC+EFV is a Small molecule drug developed by Hospital Clinic of Barcelona.
Who makes AZT+3TC+EFV?
AZT+3TC+EFV is developed and marketed by Hospital Clinic of Barcelona (see full Hospital Clinic of Barcelona pipeline at /company/hospital-clinic-of-barcelona).
What development phase is AZT+3TC+EFV in?
AZT+3TC+EFV is FDA-approved (marketed).
Related
- Manufacturer: Hospital Clinic of Barcelona — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing